Infographic | June 14, 2022

De-Risking The Supply Chain

Source: ISR Reports

In Q32021, ISR surveyed 124 sponsors who outsource small molecule drug substance and asked what strategies are they currently using or plan to use to de-risk their supply chain—a particularly pertinent topic in light of the events over the past few years, ranging from the COVID-19 pandemic to the conflict in the Ukraine. The data show that half of respondents (49%) do not currently have Redundant sourcing of CMOs, but plan to three years from now. One-third of respondents (38%) are currently investing in formulations with better shelf life to have accessible inventory.


Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Pharmaceutical Online? Subscribe today.

Subscribe to Pharmaceutical Online X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Pharmaceutical Online